Products for Research Use Only

VULM 1457

CAT: 0804-HY-107571-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-107571-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
VULM 1457 is a potent inhibitor of cholesterol acyltransferase (acyl-CoA) . VULM1457 significantly reduces production and secretion of adrenomedullin (AM) and down-regulates AM receptors on human hepatoblastic cells. VULM 1457 has remarkable hypolipidaemic activity and improves the overall myocardial ischaemia-reperfusion injury outcomes. VULM 1457 has the potential for the research of diabetes mellitus and hypercholesterolaemia[1][2].
CAS Number
228544-65-8
UNSPSC
12352005
Hazard Statement
H302, H315, H319
Target
Acyltransferase
Type
Reference compound
Related Pathways
Metabolic Enzyme/Protease
Applications
Metabolism-sugar/lipid metabolism
Field of Research
Metabolic Disease; Cardiovascular Disease
Assay Protocol
https://www.medchemexpress.com/vulm-1457.html
Purity
99.71
Solubility
DMSO : 125 mg/mL (ultrasonic)
Smiles
O=C(NC1=CC=C(SC2=CC=C([N+]([O-])=O)C=C2)C=C1)NC3=C(C=CC=C3C(C)C)C(C)C
Molecular Formula
C25H27N3O3S
Molecular Weight
449.57
Precautions
H302, H315, H319
References & Citations
[1]Adameová A, et al. The myocardial infarct size-limiting and antiarrhythmic effects of acyl-CoA:cholesterol acyltransferase inhibitor VULM 1457 protect the hearts of diabetic-hypercholesterolaemic rats against ischaemia/reperfusion injury both in vitro and in vivo. Eur J Pharmacol. 2007;576 (1-3) :114-121.|[2]J Drímal, et al. The ACAT inhibitor VULM1457 significantly reduced production and secretion of adrenomedullin (AM) and down-regulated AM receptors on human hepatoblastic cells. Gen Physiol Biophys. 2005 Dec;24 (4) :397-409.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
ACAT